Efficacy and Safety of Adalimumab as the First and Second Biologic Agent in Juvenile Idiopathic Arthritis: The German Biologics JIA Registry: Adalimumab Therapy in Juvenile Idiopathic Arthritis

Arthritis & Rheumatism(2014)

引用 24|浏览11
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要